Salmeterol + Fluticasone (Salflusol MDI) is indicated in the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2 agonist, or patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
